Early evidence suggests that the monoclonal antibody treatments will be effective against the new COVID-19 variants. We are still awaiting more specific data on this, but early indications are encouraging.
Monoclonal antibodies are a treatment for COVID-19 approved under an FDA Emergency Use Authorization (EUA). These are lab-designed antibodies that can detect the virus and help your immune system clear it. Currently, two different types of monoclonal antibody treatments have been approved: bamlanivimab and casirivimab plus imdevimab. Health care providers may recommend these treatments for those with mild to moderate COVID-19 symptoms but with a high risk of progression to severe disease.
Your doctor can help determine if monoclonal antibody treatment is appropriate for you. These treatments are still considered investigational and have shown to reduce hospitalizations and emergency room visits due to COVID-19. The CDC and FDA provide further information on their websites about these treatments: